STOCK TITAN

Stereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Stereotaxis (STXS) to release financial results for Q4 and full year 2023 on March 4, 2024. Conference call scheduled to discuss results and corporate developments.
Positive
  • None.
Negative
  • None.

ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.

  
What:Stereotaxis fourth quarter and full year 2023 financial results conference call
  
When:Monday, March 4, 2024, at 4:30 p.m. EST (1:30 p.m. PST)
  
Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 7954885.
  
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
  
Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.
  

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:                                        
David L. Fischel                                        
Chairman and Chief Executive Officer 

Kimberly Peery                                                
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

 


FAQ

When will Stereotaxis release its financial results for Q4 and full year 2023?

Stereotaxis will release its financial results for Q4 and full year 2023 on Monday, March 4, 2024.

What time is the conference call to discuss Stereotaxis' financial results scheduled for?

The conference call to discuss Stereotaxis' financial results is scheduled for Monday, March 4, 2024, at 4:30 p.m. EST.

How can I access the live call for Stereotaxis' financial results discussion?

To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 7954885.

Where can I find the webcast for Stereotaxis' financial results discussion?

To access the live and replay webcast, visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.

How long will the phone replay of the conference call be available?

A phone replay of the call will be available for one month beginning approximately four hours following the end of the call.

Stereotaxis, Inc.

NYSE:STXS

STXS Rankings

STXS Latest News

STXS Stock Data

192.18M
56.29M
15.87%
47.5%
1.13%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ST.LOUIS

About STXS

stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.